The Efficacy of Babaodan Capsules in Preventing Radiation Pneumonia
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
Radiation pneumonitis (RP) is a common complication of radiotherapy for thoracic tumors, and
the incidence rate of grade 2 or above RP is 20% -40%; The use of antibiotics after secondary
bacterial infection due to radiation pneumonia or the use of systemic glucocorticoids for
radiation pneumonia itself have significant adverse effects on the survival of NSCLC
patients. At present, FDA has not approved drugs to prevent the occurrence of radiation
pneumonia. traditional Chinese patent Babaodan (BBD) capsule has the effect of controlling
macrophages to produce proinflammatory cytokines, such as significantly inhibiting the
release of IL-6. Through prospective research, this study evaluates the incidence of
symptomatic pneumonia (G ≥ 2) in the treatment of locally advanced non-small cell lung cancer
with BBD combined with concurrent radiotherapy and chemotherapy.